市場調查報告書
商品編碼
949669

全球醫療保健發展與製造合同管理組織(CDMO)市場:2020-2026

Global Healthcare Contract Development and Manufacturing Organization (CDMO) Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,估計全球醫療保健發展與製造組織(CDMO)市場將顯著增長。市場增長受到許多因素的驅動,其中包括主要由製藥和醫療設備公司採用的合同製造和合同開發服務的增加。生物製藥生產商在研發上投入了大量資金,這為製藥生產能力留下了很大的空間。此外,據報導,製藥公司與API合同製造商之間建立了合作關係。例如,2018年1月,阿斯利康(AstraZeneca PLC)與小型通用API製造商和分子創新者Cambrex Corp.簽署了一項長期供應協議。根據合同,Cambrex將為阿斯利康提供定制的API合同製造服務。此外,由於製藥公司在遵守嚴格的政府法規方面承受的壓力越來越大,因此,製藥生產正在鼓勵製藥行業對外包服務的需求,以推動市場的進一步增長。

醫療CDMO的全球市場是按服務和地區劃分的。通過服務,市場進一步分為合同開發和合同製造。外包製造服務第一部分預計將在全球醫療CDMO市場中佔有很大佔有率,這是由於全球製藥公司大量採用了外包服務。按地區劃分,全球醫療CDMO市場進一步細分為北美,歐洲,亞太地區和其他地區。最重要的是,由於主要市場參與者的存在以及對該地區藥物研發的大量投資,預計北美地區將在全球醫療CDMO市場中佔有重要佔有率。

本報告調查了全球醫療保健發展與製造承包組織(CDMO)市場,提供了市場概況,按服務和地區劃分的趨勢以及進入該市場的公司的概況。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則與規定

第3章競爭情況

  • 公司佔有率分析
  • 主要策略分析
  • 主要公司分析
    • Catalent,Inc.
    • Lonza Group Ltd.
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Thermo Fisher Scientific Inc.

第4章市場決定因素

  • 動機
  • 抑制因子
  • 市場機會

第5章市場細分

  • 按服務分列的全球醫療保健發展與製造合同管理組織(CDMO)市場
    • 合同開發
    • 合同製造

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章公司簡介

  • AbbVie Inc.
  • Almac Group Ltd.
  • Baxter International, Inc.
  • B. Braun Melsungen AG
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Covance Inc.
  • Cambrex Corp.
  • Hisun Pharmaceuticals Inc.
  • Jabil Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group Ltd.
  • Mikart LLC
  • Pfizer Inc.
  • Probiogen AG
  • Recipharm AB
  • Siegfried Holding AG
  • Sanmina Corp.
  • Stason Pharmaceuticals, Inc.
  • Thermo Fisher Scientific Inc.
目錄
Product Code: OMR2021988

Global Healthcare Contract Development And Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) and Forecast 2020-2026

The global healthcare CDMO market is estimated to grow significantly during the forecast period. The market growth mainly backed by the various factors such as growing adoption of contract manufacturing and contract development services by the pharmaceutical and medical device companies. As biopharmaceutical companies are significantly investing in R&D, there is a significant scope for manufacturing capacity for pharmaceutical products.Further, the partnerships among pharmaceutical companies and API contract manufacturers were reported. For instance, in January 2018, AstraZeneca PLC entered into a long-term supply agreement with Cambrex Corp., a small generic API manufacturer and molecule innovator. As per the the agreement, Cambrex would provide customized API contract manufacturing services to AstraZeneca. Moreover, with the growing pressure over pharmaceutical companies to meet the stringent government regulation while the pharmaceuticals production is encouraging the demand for outsourcing services in pharmaceutical industry that further propels the market growth.

The global market for healthcare CDMO is segregated on the basis of services and region. Based on services, the market is further classified into contract development and contract manufacturing. The contract manufacturing services segment I projected to have significant share in the global healthcare CDMO market owing to the significant adoption of outsourcing servies by the pharmaceutical companies across the globe. Based on geography, the global healthcare CDMO market is further segregated into North America, Europe, Asia-Pacific and the Rest of the World. Among, region North America projected to have a considerable share in the global healthcare CDMO market owing to presence of major market players and significant investment in drug discovery and development in the region.

The companies which are contributing to the growth of the global healthcare CDMO market include Catalent, Inc., Lonza Group Ltd., Boehringer Ingelheim International GmbH, Pfizer Inc., Thermo Fisher Scientific Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.

Research Methodology

The market study of the global healthcare CDMO market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for pharmaceutical and medical devices companies for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation

1. Global Healthcare CDMO Market Research and Analysis by Services

The Report Covers:

  • Comprehensive research methodology of the global healthcare CDMO market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global healthcare CDMO market.
  • Insights about market determinants which are stimulating the global healthcare CDMO market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Catalent, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Lonza Group Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Boehringer Ingelheim International GmbH
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Pfizer Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Thermo Fisher Scientific Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Healthcare CDMO Market by Services
    • 5.1.1. Contract Development
      • 5.1.1.1. Clinical
      • 5.1.1.2. Preclinical
      • 5.1.1.3. Laboratory Services
    • 5.1.2. Contract Manufacturing
      • 5.1.2.1. Active Pharmaceutical Ingredients( API)
      • 5.1.2.2. Finish Dosage Formulations
      • 5.1.2.3. Medical Devices

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Almac Group Ltd.
  • 7.3. Baxter International, Inc.
  • 7.4. B. Braun Melsungen AG
  • 7.5. Boehringer Ingelheim International GmbH
  • 7.6. Catalent Inc.
  • 7.7. Covance Inc.
  • 7.8. Cambrex Corp.
  • 7.9. Hisun Pharmaceuticals Inc.
  • 7.10. Jabil Inc.
  • 7.11. Jubilant Life Sciences Ltd.
  • 7.12. Lonza Group Ltd.
  • 7.13. Mikart LLC
  • 7.14. Pfizer Inc.
  • 7.15. Probiogen AG
  • 7.16. Recipharm AB
  • 7.17. Siegfried Holding AG
  • 7.18. Sanmina Corp.
  • 7.19. Stason Pharmaceuticals, Inc.
  • 7.20. Thermo Fisher Scientific Inc.

LIST OF TABLES

  • 1. GLOBAL HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY SERVICES, 2019-2026 ($ MILLION)
  • 2. GLOBAL CONTRACT DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 5. NORTH AMERICAN HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 6. NORTH AMERICAN HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY SERVICES, 2019-2026 ($ MILLION)
  • 7. EUROPEAN HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 8. EUROPEAN HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY SERVICES, 2019-2026 ($ MILLION)
  • 9. ASIA-PACIFIC HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. ASIA-PACIFIC HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY SERVICES, 2019-2026 ($ MILLION)
  • 11. REST OF THE WORLD HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY SERVICES, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HEALTHCARE CDMO MARKET SHARE BY SERVICES, 2019 VS 2026 (%)
  • 2. GLOBAL HEALTHCARE CDMO MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)